Home | Find A Doctor | Contact Us


Abiraterone Acetate Treatment for Prostate Cancer Patients with PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II

Principal Investigator: Seth Cohen, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai West


Continuum Cancer Research Program
(212) 844-6286


This study aims to treat patients with prostate cancer who have failed androgen deprivation therapy.

Developing data suggests that the low levels of androgens that persist, despite androgen deprivation therapy, may play an important role in the development of castrate resistant prostate cancer (CRPC). Current therapies (orchiectomy and GNRH) cut androgen production by the testes but do not affect androgen production by the adrenals.

Abiraterone inhibits the conversion of progesterone into androstenedione, which are 2 precursors of testosterone in the adrenal glands and testes. Testosterone is further converted to the more potent androgen dihydrotestosterone (DHT). Both testosterone and DHT stimulate prostatic growth.

Eligibility and Treatment Plan:
• Male
• Age = 18
• Adenocarcinoma of the prostate
• Metastatic
• Receiving androgen deprivation therapy
• No prior cytotoxic chemotherapy or radiopharmaceuticals for prostate cancer
• No patients with a history of brain metastases or currently have treated or untreated brain metastases

Please call for more information.



Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System